A study to evaluate the use of CHF6001 DPI in adult asthmatics

• Research type

  Research Study

• Full title

  A randomised, double-blind, placebo-controlled, three-way crossover study to evaluate the efficacy after allergen challenge, safety and tolerability of two doses of inhaled CHF6001 DPI after 9 days of treatment in adult patients with asthma.

• IRAS ID

  109262

• Contact name

  S D Singh

• Sponsor organisation

  Chiesi Farmaceutici S.p.A.

• Eudract number

  2012-001483-29

• Research summary

  A study to investigate the use of an inhaled anti-inflammatory (CHF6001 DPI) in adults with mild to moderate allergic asthma. Following 9 days of treatment, an allergen challenge test will be performed to assess if a low or high dose of CHF6001 has any preventive effect on the subject??s symptoms.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  12/NW/0470

• Date of REC Opinion

  8 Aug 2012

• REC opinion

  Further Information Favourable Opinion